{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:24Z","timestamp":1793946444984,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020207","name":"Sichuan Province Health Commission","doi-asserted-by":"publisher","award":["2025-1702"],"award-info":[{"award-number":["2025-1702"]}],"id":[{"id":"10.13039\/501100020207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105492","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:52:00Z","timestamp":1784271120000},"page":"105492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Current status and prospects of chemotherapy-free strategies in ovarian cancer"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7718-9777","authenticated-orcid":false,"given":"Caixia","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-2059","authenticated-orcid":false,"given":"Zhengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.critrevonc.2026.105492_bib1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-026-09750-w","article-title":"Efficacy of chimeric antigen receptor natural killer cells in treatment of ovarian cancer. A meta-analysis of pre-clinical studies","volume":"74","author":"Ahmed","year":"2026","journal-title":"Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drup.2015.11.005","article-title":"Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions","volume":"24","author":"Alkema","year":"2016","journal-title":"Drug. Resist. Updates"},{"key":"10.1016\/j.critrevonc.2026.105492_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2026.101295","article-title":"Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors","volume":"74","author":"Almaraz-Postigo","year":"2026","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105492_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib6","article-title":"Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer","author":"Azani","year":"2025","journal-title":"Stem Cell. Rev. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J. ovarian Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189224","article-title":"Biomarkers in high grade serous ovarian cancer","volume":"1879","author":"Bates","year":"2024","journal-title":"Biochim. Et. Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105492_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40801-022-00349-9","article-title":"Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study","volume":"10","author":"Bellier","year":"2023","journal-title":"Drugs - Real. World Outcomes"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105492_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: Clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2024","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.critrevonc.2026.105492_bib12","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2026.37.e49","article-title":"The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial","volume":"37","author":"Bogani","year":"2026","journal-title":"J. Gynecol. Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105492_bib13","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA Trial","volume":"37","author":"Campo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105492_bib14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105492_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112112","article-title":"Prospects and challenges of CAR-T in the treatment of ovarian cancer","volume":"133","author":"Chen","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13048-024-01523-z","article-title":"ADC: a deadly killer of platinum resistant ovarian cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. ovarian Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib18","article-title":"BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer","author":"Chiello","year":"2025","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/cells15040373","article-title":"Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors","volume":"15","author":"Chung","year":"2026","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105492_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"issue":"2025","key":"10.1016\/j.critrevonc.2026.105492_bib22","first-page":"S1697","article-title":"LBA3 Pembrolizumab vs placebo plus weekly paclitaxel\u00b1bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2025","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105492_bib23","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.3390\/cancers15123220","article-title":"Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery","volume":"15","author":"Colombo","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/annonc\/mdx218","article-title":"Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment","volume":"28","author":"Condorelli","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105492_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102818","article-title":"De-escalation in stage IC epithelial ovarian cancer: adjuvant treatment","volume":"36","author":"Dagher","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105492_bib26","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105492_bib27","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","article-title":"Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors","volume":"27","author":"Do","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","article-title":"Breast Cancer Resistance Protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)","volume":"32","author":"Durmus","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib29","first-page":"1","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105492_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejca.2021.02.006","article-title":"Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting","volume":"148","author":"Francis","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105492_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2024.11.004","article-title":"Adverse events in the placebo arm of SOLO2\/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer","volume":"192","author":"Francis","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105492_bib32","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-21-3023","article-title":"Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)","volume":"28","author":"Gao","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105492_bib33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","article-title":"Treatment of ovarian cancer beyond PARP Inhibition: current and future options","volume":"83","author":"Garg","year":"2023","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105492_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71208","article-title":"Sensitivity of platinum-based chemotherapy and efficacy of arsenic trioxide-based non-platinum chemotherapy following the progression ofPARPi maintenance therapy: a real-world study","volume":"14","author":"Gou","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105492_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2025.06.017","article-title":"Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma","volume":"199","author":"Greenman","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189374","article-title":"The VEGF\/VEGFR2 system in ovarian cancer: from functional to pharmacological significance","volume":"1880","author":"Grillo","year":"2025","journal-title":"Biochim. Et. Biophys. Acta Rev. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105492_bib37","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12916-024-03420-0","article-title":"IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer","volume":"22","author":"Guo","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2026.105492_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"701","key":"10.1016\/j.critrevonc.2026.105492_bib40","doi-asserted-by":"crossref","first-page":"eadd7872","DOI":"10.1126\/scitranslmed.add7872","article-title":"BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor\u2013resistant BRCA -mutant ovarian cancer","volume":"15","author":"Gupta","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12885-025-13640-z","article-title":"The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model","volume":"25","author":"Gupta","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105492_bib42","first-page":"S923","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","author":"Harter","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105492_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101978","article-title":"Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets","volume":"35","author":"He","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105492_bib44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/0008-5472.CAN-23-1429","article-title":"Serial Circulating Tumor DNA Analysis with a Tumor-Na\u00efve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer","volume":"84","author":"Heo","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105492_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ygyno.2021.02.024","article-title":"Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis","volume":"161","author":"Huang","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12905-023-02879-y","article-title":"Efficacy and safety of VEGF\/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Women's. Health"},{"key":"10.1016\/j.critrevonc.2026.105492_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","article-title":"New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug. Resist. Updates"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105492_bib48","article-title":"A Phosphatidylinositol 3-Kinase Gamma Inhibitor Enhances Anti-Programmed Death-1\/Programmed Death Ligand-1 Antitumor Effects by Remodeling the Tumor Immune Microenvironment of Ovarian Cancer","volume":"6","author":"Jiang","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.critrevonc.2026.105492_bib49","first-page":"1","article-title":"Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy","volume":"2022","author":"Jin","year":"2022","journal-title":"J. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105492_bib50","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105492_bib51","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105492_bib52","article-title":"Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity","volume":"8","author":"Korsholm","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105492_bib53","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE\/ENGOT-ov29 Trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib54","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105492_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102819","volume":"36","author":"Lafferty","year":"2026","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105492_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"42","author":"Laurent","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib57","article-title":"Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer","author":"Le Saux","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105492_bib58","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/cncr.33517","article-title":"Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis","volume":"127","author":"Lee","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105492_bib59","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.trecan.2019.06.004","article-title":"Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer","volume":"5","author":"Lee","year":"2019","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105492_bib60","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/1078-0432.CCR-24-3877","article-title":"Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial","volume":"31","author":"Lee","year":"2025","journal-title":"Clinic. cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2025.07.006","volume":"199","author":"Lee","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105492_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112792","article-title":"ATR protects ongoing and newly assembled DNA replication forks through distinct mechanisms","volume":"42","author":"Leung","year":"2023","journal-title":"Cell. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105492_bib63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105492_bib64","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105492_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00693","article-title":"Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort a of the OPAL phase II trial","author":"Liu","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105492_bib66","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3","volume":"22","author":"Liu","year":"2024","journal-title":"2024. J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2026.105492_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1713163","article-title":"Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis","volume":"15","author":"Liu","year":"2026","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib68","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib69","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdz079","article-title":"Chemotherapy-free treatments: are we ready for prime time?","volume":"30","author":"Lorusso","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ijgc-2022-003719","article-title":"Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?","volume":"33","author":"Marques","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105492_bib72","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib73","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105492_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf990","article-title":"Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance","volume":"53","author":"McGehee","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105492_bib77","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105492_bib78","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105492_bib79","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105492_bib80","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105492_bib81","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib82","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-21-0191","article-title":"New therapeutic opportunities for women with low-grade serous ovarian cancer","volume":"29","author":"Moujaber","year":"2021","journal-title":"Endocr. -Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105492_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102458","article-title":"MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis","volume":"110","author":"Musacchio","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105492_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-025-03448-3","article-title":"Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment","author":"Narayana","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105492_bib85","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-0654","article-title":"Selective Alanine Transporter Utilization is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer","author":"Nie","year":"2025","journal-title":"Cancer Res."},{"issue":"10421","key":"10.1016\/j.critrevonc.2026.105492_bib86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105492_bib87","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426743122","article-title":"BRCA2 reversion mutation\u2013independent resistance to PARP inhibition through impaired DNA prereplication complex function","volume":"122","author":"Pappas","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13048-025-01911-z","article-title":"Genomic complexity and evolution of high-grade serous ovarian cancer treated with platinum-based chemotherapy: advancing precision oncology beyond BRCA1\/BRCA2","volume":"19","author":"Pokorna","year":"2026","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2025.04.580","article-title":"Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and\/or BRCA2 mutation: Final overall survival results from the OPINION trial","volume":"197","author":"Poveda","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105492_bib90","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105492_bib91","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib92","article-title":"Biomarker-driven Targeted Therapy in Platinum-Resistant Ovarian Cancer (PROC): Results from the BRIGHT","author":"Q","year":"2025","journal-title":"Trial 2025 Sgo."},{"key":"10.1016\/j.critrevonc.2026.105492_bib93","unstructured":"Q, G., H, Z., H, Z., R, A., J, J., & Q, L., et al. (2025b). Biomarker-driven Targeted Therapy in Platinum-Resistant Ovarian Cancer (PROC): Results from the BRIGHT Trial."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib94","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/0008-5472.CAN-23-4129","article-title":"AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy","volume":"84","author":"Ramanarayanan","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jsbmb.2014.02.010","article-title":"Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer","volume":"143","author":"Ribeiro","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib96","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105492_bib97","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S1470-2045(19)30492-9","article-title":"Chemotherapy-free, but not quite free chemotherapy","volume":"20","author":"Schorge","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105492_bib99","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","article-title":"Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review","volume":"162","author":"Secord","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105492_bib100","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038216","article-title":"Prevention of Epithelial Ovarian Cancer","volume":"13","author":"Sellers","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105492_bib101","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","journal-title":"Med. J. Aust."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib102","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib103","doi-asserted-by":"crossref","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in Ovarian Cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch. Immunol. Et. Ther. Exp."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105492_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104611","article-title":"Ovarian cancer-epidemiology, classification, pathogenesis, treatment, and estrogen receptors' molecular backgrounds","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105492_bib105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ijgc-2022-003698","article-title":"Overcoming PARP inhibitor resistance in ovarian cancer","volume":"33","author":"Soberanis Pina","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105492_bib106","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib107","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","article-title":"The RAS-MEK-ERK pathway in low-grade serous ovarian cancer","volume":"200","author":"Stover","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2025.04.584","article-title":"Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort","volume":"197","author":"Suh-Burgmann","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105492_bib109","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.7150\/thno.104858","article-title":"Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation","volume":"15","author":"Sun","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105492_bib110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/gpm-24-20","article-title":"Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004","volume":"8","author":"Taira","year":"2024","journal-title":"Gynecol. Pelvic Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105492_bib111","doi-asserted-by":"crossref","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","article-title":"Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer","volume":"20","author":"Tang","year":"2024","journal-title":"Cancer Biol. & Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105492_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103984","article-title":"Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights","volume":"9","author":"Tuninetti","year":"2024","journal-title":"ESMO Open."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105492_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib114","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105492_bib115","first-page":"10","article-title":"Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K\/AKT\/mTOR pathway","author":"Wang","year":"2025","journal-title":"J. ovarian Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105492_bib116","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105492_bib117","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.critrevonc.2026.105492_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116349","article-title":"CAR-T therapy for ovarian cancer: Recent advances and future directions","volume":"226","author":"Xin","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105492_bib119","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/ijgc-2024-005351","article-title":"Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study","volume":"34","author":"Xu","year":"2024","journal-title":"International journal gynecological cancer official journal International Gynecological Cancer Society"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105492_bib120","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-11-1219","article-title":"Overcoming Antiangiogenic Resistance","volume":"17","author":"Yao","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib121","doi-asserted-by":"crossref","unstructured":"Yuan, G., Lou, G., Li, J., Xu, M., Liu, X., & Wang, D., et al. (2026). Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. Nature Cancer.","DOI":"10.1038\/s43018-025-01085-z"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105492_bib122","article-title":"Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer","volume":"11","author":"Zeng","year":"2024","journal-title":"Mil. Med. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105492_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22257","article-title":"A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies","volume":"85","author":"Zhao","year":"2024","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.critrevonc.2026.105492_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115724","article-title":"Strategies to synergize PD-1\/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer","volume":"215","author":"Zhao","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140767","article-title":"A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective","volume":"304","author":"Zhao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105492_bib126","first-page":"221","article-title":"Cancer incidence and mortality in China, 2022. Zh\u014dnghu\u00e1 zh\u014fngli","volume":"46","author":"Zheng","year":"2024","journal-title":"\u00fa Z. \u00e1Zh. \u00ec"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105492_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30714-4","article-title":"Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer","volume":"20","author":"Zhou","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105492_bib128","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Zhou, J., Wang, Y., Li, J., Luo, R., & Zeng, C., et al. (2025). Albumin-bound paclitaxel plus anlotinib in patients with recurrent, platinum-resistant primary epithelial ovarian cancer (A-Plus): a phase II, single-arm, prospective study. Frontiers of Medicine.","DOI":"10.1007\/s11684-025-1155-1"},{"key":"10.1016\/j.critrevonc.2026.105492_bib129","article-title":"Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort study","volume":"11","author":"Zucker","year":"2026","journal-title":"ESMO Real. World Data Digit. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:37:15Z","timestamp":1793943435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":129,"alternative-id":["S1040842826003793"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105492","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and prospects of chemotherapy-free strategies in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105492"}}